Fig. 7: MAPK inhibitors upregulate HER2 expression. | Nature Communications

Fig. 7: MAPK inhibitors upregulate HER2 expression.

From: Combined KRAS-MAPK pathway inhibitors and HER2-directed drug conjugate is efficacious in pancreatic cancer

Fig. 7

a Representative IHC images showing changes in HER2 protein expression in the indicated PDAC xenografts using a CLIA-certified HER2 staining kit routinely used for the analysis of gastric cancer samples, Scale bars = 20 μM. b Representative FACS plots and quantification showing changes in surface (without cell permeabilization) and total (with cell permeabilization) HER2 abundance following 16 h treatment as indicated (ulixertinib 2 μM, trametinib 0.5 μM, DS-8201a 0.1 μg/ml). Data represents one of three independent experiments each done in triplicates. Data are presented as the mean ± SEM. P-values were calculated using unpaired t-test with Welch’s correction or ANOVA followed by Tukey’s test. c Representative IF images showing increased surface and total HER2 expression (red) in Pa01c cells treated for 16 h with the indicated agents as (b). LysoTracker Green DND-26 was used to stain the endolysosomes, Scale bars = 50 μM. d Western blots showing suppression of MAPK activity and upregulation of DUSP6 in Pa01c cells after treatment with vehicle or DS-8201a 0.1 μg/ml for 16 h. d was conducted two times, and one set of data was presented. All data are provided in Source Data file.

Back to article page